Renal Cell Carcinoma malady

Genetic diseases, Nephrological diseases, Cancer diseases, Rare diseases categories

Aliases & Classifications for Renal Cell Carcinoma

About this section
46OMIM, 30LifeMap Discovery®, 8Disease Ontology, 9diseasecard, 10DISEASES, 48Orphanet, 22GTR, 61UMLS, 33MeSH, 56SNOMED-CT, 39NCIt, 26ICD10 via Orphanet, 62UMLS via Orphanet, 34MESH via Orphanet
See all sources

Aliases & Descriptions for Renal Cell Carcinoma:

Name: Renal Cell Carcinoma 46 30 8 10 48 61
Renal Carcinoma, Chromophobe, Somatic 46 9
Nonpapillary Renal Cell Carcinoma 8 22
Rcc 8 48
Renal Cell Carcinoma, Clear Cell, Somatic 46
Conventional Renal Cell Carcinoma 61
Renal Cell Carcinoma, Nonpapillary 61
Renal Cell Carcinoma, Somatic 46
Adenocarcinoma of Kidney 8
Hypernephroma 8


Characteristics (Orphanet epidemiological data):

renal cell carcinoma:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult

External Ids:

OMIM46 144700
Disease Ontology8 DOID:0050387, DOID:4450
MeSH33 D002292
NCIt39 C9385
SNOMED-CT56 41607009, 254915003
Orphanet48 217071
ICD10 via Orphanet26 C64
UMLS via Orphanet62 C0007134
MESH via Orphanet34 D002292

Summaries for Renal Cell Carcinoma

About this section
OMIM:46 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant... (144700) more...

MalaCards based summary: Renal Cell Carcinoma, also known as renal carcinoma, chromophobe, somatic, is related to renal oncocytoma and kidney cancer, and has symptoms including sporadicand renal cell carcinoma. An important gene associated with Renal Cell Carcinoma is VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase), and among its related pathways are Regulation of beta-cell development and Renal cell carcinoma. The drugs hydroxyurea and interferon alfa-2a and the compounds nnmt and glucose have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related mouse phenotypes are liver/biliary system and renal/urinary system.

Disease Ontology:8 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Novus Biologicals:45 Renal cell carcinoma originates in the proximal renal tube and is the most common form of kidney cancer. Renal cell carcinoma is resistant to radiation therapy and chemotherapy, however some cases respond to immunotherapy. Interleukin-2 has produced remission in some patients, as has functional restoration of the VHL gene.

Wikipedia:64 Renal cell carcinoma (RCC, also known as hypernephroma, Grawitz tumor, renal adenocarcinoma) is a kidney... more...

Related Diseases for Renal Cell Carcinoma

About this section

Diseases in the Renal Cell Carcinoma family:

Renal Clear Cell Carcinoma Hereditary Renal Cell Carcinoma
Familial Renal Cell Carcinoma Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 369)
idRelated DiseaseScoreTop Affiliating Genes
1renal oncocytoma32.3FLCN, PRCC
2kidney cancer31.9FLCN, MET, VHL, CA9
3sarcoma31.8CA9, MET, TFE3
4cystic kidney31.5VHL, HNF1B
5von hippel-lindau syndrome31.5MET, VHL
6renal clear cell carcinoma31.5CA9, VHL, MET, MME
7alveolar soft-part sarcoma31.4TFE3, ASPSCR1, PRCC
8papillary adenoma31.4PRCC
9cystadenoma31.3MME, VHL
10adenocarcinoma31.3MME, MET, VHL, CA9, HNF1B, OGG1
11birt-hogg-dube syndrome31.3FLCN
12adenoma31.3MET, VHL, HNF1A, OGG1
13colorectal cancer31.0MET, CA9, HNF1A, OGG1
14cholangiocarcinoma30.9MME, MET, OGG1
15polycystic kidney disease30.8HNF1B, VHL
16breast cancer30.7MME, MET, VHL, CA9, HNF1A, OGG1
17hepatocellular carcinoma30.7MME, MET, HNF1B, HNF1A, OGG1
18clear cell renal cell carcinoma11.4
19chromophobe renal cell carcinoma11.2
20sarcomatoid renal cell carcinoma11.1
22clear cell papillary renal cell carcinoma10.9
24multilocular cystic renal cell carcinoma10.9
27renal cell carcinoma, papillary10.8
28translocation renal cell carcinoma10.8
29kidney disease10.8
30familial renal cell carcinoma10.8
31hereditary renal cell carcinoma10.7
33horseshoe kidney10.7
36tuberous sclerosis10.6
38oxyphilic adenoma10.6FLCN, MME, VHL, CA9
39xanthogranulomatous pyelonephritis10.6
40chromophil renal cell carcinoma10.6
43collecting duct carcinoma10.6
44cerebral palsy10.6ASPSCR1
45lung cancer10.5OGG1, CA9, VHL, MET
50renal cell carcinoma 410.5

Graphical network of the top 20 diseases related to Renal Cell Carcinoma:

Diseases related to renal cell carcinoma

Symptoms for Renal Cell Carcinoma

About this section

Clinical features from OMIM:


HPO human phenotypes related to Renal Cell Carcinoma:

id Description Frequency HPO Source Accession
1 sporadic HP:0003745
2 renal cell carcinoma HP:0005584

Drugs & Therapeutics for Renal Cell Carcinoma

About this section

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
Avastin13 38 BEVACIZUMAB Genentech Approved July 2009
FDA Label: Avastin
Malady that Drug Treats: renal cell carcinoma & Colorectal Cancer
Indications and Usage:13 Avastin is a vascular endothelial growth factor-specific angiogenesis; inhibitor indicated for the treatment of:; Metastatic colorectal cancer, with intravenous 5-fluorouracil-based; chemotherapy for first- or second-line treatment. (1.1); Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or; fluoropyrimidine-oxaliplatin-based chemotherapy for second-line; treatment in patients who have progressed on a first-line Avastincontaining; regimen. (1.1); Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel; for first line treatment of unresectable, locally advanced, recurrent or; metastatic disease. (1.2); Glioblastoma, as a single agent for adult patients with progressive disease; following prior therapy. (1.3); -Effectiveness based on improvement in objective response rate. No data; available demonstrating improvement in disease-related symptoms or; survival with Avastin.; Metastatic renal cell carcinoma with interferon alfa (1.4); Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel; and topotecan in persistent, recurrent, or metastatic disease. (1.5); Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary; peritoneal cancer, in combination with paclitaxel, pegylated liposomal; doxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of colon; cancer. (1.1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR); 697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial; 698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration; 699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction; 700 of microvascular growth and inhibition of metastatic disease progression
Inlyta13 38 AXITINIB Pfizer Approved January 2012
FDA Label: Inlyta
Malady that Drug Treats: advanced renal cell carcinoma
Indications and Usage:13 INLYTA is a kinase inhibitor indicated for the treatment of advanced; renal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3
Mechanism of Action:13 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth; factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These; receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediated; endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse; models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft; mouse models.
Nexavar13 38 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
FDA Label: Nexavar
Malady that Drug Treats: Renal Cell Carcinoma
Indications and Usage:13 NEXAVAR is a kinase inhibitor indicated for the treatment of ; Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12); Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:11 1. Serine/threonine-protein kinase B-raf; 2. RAF proto-oncogene serine/threonine-protein kinase; 3. Vascular endothelial growth factor receptor 3; 4. Vascular endothelial growth factor receptor 2; 5. Receptor-type tyrosine-protein kinase FLT3; 6. Platelet-derived growth factor receptor beta; 7. Mast/stem cell growth factor receptor Kit; 8. Fibroblast growth factor receptor 1; 9. Proto-oncogene tyrosine-protein kinase receptor Ret; 10. Vascular endothelial growth factor receptor 1
Mechanism of Action:13 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.; Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface; kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these; kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor; growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor; angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis; wer e obser ved in models of HCC, RCC, and DTC.
Proleukin13 38 ALDESLEUKIN Chiron Approved January 1998
FDA Label: Proleukin
Malady that Drug Treats: Metastatic melanoma
Indications and Usage:13 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell; carcinoma (metastatic RCC).; Proleukin is indicated for the treatment of adults with metastatic melanoma.; Careful patient selection is mandatory prior to the administration of Proleukin. See;  CONTRAINDICATIONS ,  WARNINGS and  PRECAUTIONS sections regarding patient; screening, including recommended cardiac and pulmonary function tests and laboratory; tests.; Evaluation of clinical studies to date reveals that patients with more favorable ECOG; performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a; higher response rate and lower toxicity (See  CLINICAL PHARMACOLOGY section,;  CLINICAL STUDIES section and  ADVERSE REACTIONS section). Therefore, selection; of patients for treatment should include assessment of performance status.; Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:11 1. Interleukin-2 receptor subunit beta; 2. Interleukin-2 receptor subunit alpha; 3. Cytokine receptor common subunit gamma
Mechanism of Action:13 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocyte; mitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human native; interleukin-2.1,2 In vitro studies performed on human cell lines demonstrate the; immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte; mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated; (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.; The in vivo administration of Proleukin in animals and humans produces multiple; immunological effects in a dose dependent manner. These effects include activation of; cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the; production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivo; experiments in murine tumor models have shown inhibition of tumor growth.4; The exact; mechanism by which Proleukin mediates its antitumor activity in animals and humans is; unknown.
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.
Torisel13 38 TEMSIROLIMUS Wyeth Approved May 2007
FDA Label: Torisel
Malady that Drug Treats: renal cell carcinoma
Indications and Usage:13 TORISEL® is a kinase inhibitor indicated for the treatment of advanced renal; cell carcinoma. (1)
DrugBank Targets:11 1. Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to; an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR; that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated; tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal; protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In; in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR; and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the; vascular endothelial growth factor.
Votrient13 38 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009
FDA Label: Votrient
Malady that Drug Treats: soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:13 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with:; advanced renal cell carcinoma. (1); advanced soft tissue sarcoma who have received prior chemotherapy. (1); Limitation of Use: The efficacy of VOTRIENT for the treatment of patients; with adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has not; been demonstrated.
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3; 4. Platelet-derived growth factor receptor alpha; 5. Platelet-derived growth factor receptor beta; 6. Mast/stem cell growth factor receptor Kit; 7. Fibroblast growth factor receptor 3; 8. Tyrosine-protein kinase ITK/TSK; 9. Fibroblast growth factor 1; 10. SH2B adapter protein 3
Mechanism of Action:13 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor; receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-±; and -², fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2; receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and; transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited; ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-² receptors. In vivo,; pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in; a mouse model, and the growth of some human tumor xenografts in mice.

Drug clinical trials:

Search ClinicalTrials for Renal Cell Carcinoma

Search NIH Clinical Center for Renal Cell Carcinoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Renal Cell Carcinoma

About this section

Genetic tests related to Renal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary22

Anatomical Context for Renal Cell Carcinoma

About this section

MalaCards organs/tissues related to Renal Cell Carcinoma:

Kidney, Endothelial, T cells, Bone, Thyroid, Lung, Prostate, Brain, Lymph node, Liver, Myeloid, Skin, Monocytes, Breast, Testes, B cells, Testis, Neutrophil, Cortex, Pituitary, Smooth muscle, Bone marrow, Heart, Colon, Pancreas, Nk cells, Spinal cord, Small intestine, Adrenal gland, Tongue, Whole blood, Spleen, Skeletal muscle, Salivary gland, Ovary, Placenta

Animal Models for Renal Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Renal Cell Carcinoma:

idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537010.5OGG1, MME, PBRM1, MET, VHL, HNF1B
2MP:000536710.5HNF1A, HNF1B, VHL, MET, FLCN
3MP:001076810.4TFE3, FLCN, PBRM1, MET, VHL, CA9
4MP:000538010.3FLCN, PBRM1, MET, VHL, HNF1B, NONO
5MP:000537610.1FLCN, MME, MET, VHL, HNF1B, HNF1A

Publications for Renal Cell Carcinoma

About this section

Articles related to Renal Cell Carcinoma:

(show top 50)    (show all 4337)
Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. (24060356)
Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. (23696916)
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. (23272732)
Attenuation of krA1ppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma. (23861801)
Effects of TGF-I^ signaling in clear cell renal cell carcinoma cells. (23618868)
Double jeopardy? Renal-sparing management of simultaneous ipsilateral renal cell carcinoma and urothelial carcinoma. (23914271)
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. (23799843)
Fibronectin 1 protein expression in clear cell renal cell carcinoma. (22740994)
Alterations of the WNT7A gene in clear cell renal cell carcinomas. (23056560)
Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. (21229250)
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. (21632985)
Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease. (21496837)
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. (20103651)
Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. (20121140)
A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. (19573980)
Increased activated Akt expression in renal cell carcinomas and prognosis. (18774962)
Imprint cytologic features in renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in an adult: a case report. (20014561)
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. (19581925)
MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1. (18709334)
Renal cell carcinoma and antiangiogenic therapies]. (18035517)
Organ-confined clear cell renal cell carcinoma: the prognostic impact of microvascular invasion, nuclear grade and tumour size. (19133004)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. (17605814)
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. (16644575)
Renal cell carcinoma with an Xp11.2 translocation in a 16-year-old girl: a case report with cytological features. (17121199)
Chromophobe renal cell carcinoma with focal papillary configuration, nuclear basaloid arrangement and stromal osseous metaplasia containing fatty bone marrow element. (15910607)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (15625368)
Experimental study on induction of renal cell carcinoma apoptosis by antisense oligonucleotide targeting survivin. (15641694)
Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. (14654968)
Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma. (14981959)
Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. (12963978)
Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. (11986770)
Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. (11369057)
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. (11139287)
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. (10537342)
Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. (9205056)
Temporal arteritis presenting with concomitant renal cell carcinoma. (19078210)
An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. (8660841)
Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. (7861551)
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. (8198979)
Sarcomatoid renal cell carcinoma. A study of its proliferative activity. (8095849)
Immunological study of interferon-gamma therapy for advanced renal cell carcinoma]. (1288223)
Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. (1739130)
Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma. (1598724)
Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma. (1795011)
In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. (2111411)
Comparative biochemical and immunological studies on gamma-glutamyltransferases from human kidney and renal cell carcinoma applying monoclonal antibodies. (1979761)
Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. (2185803)
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. (2894030)
Reversible renal hypertension secondary to renal arteriovenous fistula and renal cell carcinoma. (833981)

Variations for Renal Cell Carcinoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma:

id Symbol AA change Variation ID SNP ID

Cosmic variations for Renal Cell Carcinoma:

6 (show all 51)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
1690METkidney,NS,carcinoma,papillary renal cell carcinoma3
2704METkidney,NS,carcinoma,papillary renal cell carcinoma3
3698METkidney,NS,carcinoma,papillary renal cell carcinoma3
4689METkidney,NS,carcinoma,papillary renal cell carcinoma3
5484661METkidney,NS,carcinoma,papillary renal cell carcinoma3
6697METkidney,NS,carcinoma,papillary renal cell carcinoma3
7696METkidney,NS,carcinoma,papillary renal cell carcinoma3
8688METkidney,NS,carcinoma,papillary renal cell carcinoma3
9691METkidney,NS,carcinoma,papillary renal cell carcinoma3
1010670TP53kidney,NS,carcinoma,chromophobe renal cell carcinoma3
1110659TP53kidney,NS,carcinoma,chromophobe renal cell carcinoma3
1210709TP53kidney,NS,carcinoma,papillary renal cell carcinoma3
1345322TP53kidney,NS,carcinoma,chromophobe renal cell carcinoma3
1411450TP53kidney,NS,carcinoma,chromophobe renal cell carcinoma3
1543697TP53kidney,NS,carcinoma,papillary renal cell carcinoma3
1611071TP53kidney,NS,carcinoma,chromophobe renal cell carcinoma3
1743850TP53kidney,NS,carcinoma,papillary renal cell carcinoma3
1817807VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
1914311VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
2018346VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
2118028VHLkidney,NS,carcinoma,chromophobe renal cell carcinoma3
2230286VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
2317808VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
2425673VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
25760PIK3CAkidney,NS,carcinoma,papillary renal cell carcinoma3
26763PIK3CAkidney,NS,carcinoma,papillary renal cell carcinoma3
27718FGFR3kidney,NS,carcinoma,papillary renal cell carcinoma3
283993568FGFR3kidney,NS,carcinoma,papillary renal cell carcinoma3
29462BRAFkidney,NS,carcinoma,papillary renal cell carcinoma3
301131BRAFkidney,NS,carcinoma,papillary renal cell carcinoma3
3121945EGFRkidney,NS,carcinoma,papillary renal cell carcinoma3
3214060ERBB2kidney,NS,carcinoma,papillary renal cell carcinoma3
331583146DNMT3Akidney,NS,carcinoma,papillary renal cell carcinoma3
341181978ADARB1kidney,NS,carcinoma,papillary renal cell carcinoma3
35742462GFRALkidney,NS,carcinoma,papillary renal cell carcinoma3
36375283ANKHD1-EIF4EBP3kidney,NS,carcinoma,papillary renal cell carcinoma3
37274461CDC73kidney,NS,carcinoma,papillary renal cell carcinoma3
38302052DHX9kidney,NS,carcinoma,papillary renal cell carcinoma3
39375284ANKHD1kidney,NS,carcinoma,papillary renal cell carcinoma3
40964299MAP2K5kidney,NS,carcinoma,papillary renal cell carcinoma3
41485065RHEBkidney,NS,carcinoma,papillary renal cell carcinoma3
421222993RAD23Bkidney,NS,carcinoma,papillary renal cell carcinoma3
43487039SCAIkidney,NS,carcinoma,papillary renal cell carcinoma3
44110414SMARCB1kidney,NS,carcinoma,papillary renal cell carcinoma3
451268384TP63kidney,NS,carcinoma,papillary renal cell carcinoma3
461360764SOX5kidney,NS,carcinoma,papillary renal cell carcinoma3
475260PTENkidney,NS,carcinoma,papillary renal cell carcinoma3
48485575PMS2P11kidney,NS,carcinoma,papillary renal cell carcinoma3
49521KRASkidney,NS,carcinoma,papillary renal cell carcinoma3
50188258HIVEP3kidney,NS,carcinoma,papillary renal cell carcinoma3
51163384PDGFRAkidney,NS,carcinoma,papillary renal cell carcinoma3

Expression for genes affiliated with Renal Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma patients vs. healthy controls: 30 (show all 89)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1ANGPTL4angiopoietin-like 4Kidney+7.250.000
2TNFAIP6tumor necrosis factor, alpha-induced protein 6Kidney+7.160.000
3APOC1apolipoprotein C-IKidney+6.110.000
4NPTX2neuronal pentraxin IIKidney+6.050.000
5PTHLHparathyroid hormone-like hormoneKidney+5.880.001
6NDUFA4L2NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2Kidney+5.760.000
7FABP7fatty acid binding protein 7, brainKidney+5.710.042
8CCL20chemokine (C-C motif) ligand 20Kidney+5.550.007
9CDCA2cell division cycle associated 2Kidney+5.520.000
10STC2stanniocalcin 2Kidney+5.390.000
11TOP2Atopoisomerase (DNA) II alpha 170kDaKidney+5.240.000
12EGLN3egl-9 family hypoxia-inducible factor 3Kidney+5.120.000
13NKG7natural killer cell granule protein 7Kidney+5.070.000
14NNMTnicotinamide N-methyltransferaseKidney+5.050.000
15FABP6fatty acid binding protein 6, ilealKidney+4.940.005
16CA9carbonic anhydrase IXKidney+4.920.000
17ISG20interferon stimulated exonuclease gene 20kDaKidney+4.890.000
18HK2hexokinase 2Kidney+4.710.000
19KISS1RKISS1 receptorKidney+4.670.001
20ARL11ADP-ribosylation factor-like 11Kidney+4.600.000
21C5orf46chromosome 5 open reading frame 46Kidney+4.590.016
22C3complement component 3Kidney+4.550.000
23CTHRC1collagen triple helix repeat containing 1Kidney+4.540.000
24CD300ACD300a moleculeKidney+4.490.001
25CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Kidney+4.450.012
26SLAMF7SLAM family member 7Kidney+4.450.001
27MIR155HGMIR155 host gene (non-protein coding)Kidney+4.440.001
28SLFN13schlafen family member 13Kidney+4.320.000
29SLC16A3solute carrier family 16 (monocarboxylate transporter), member 3Kidney+4.240.000
30FAM26Ffamily with sequence similarity 26, member FKidney+4.180.000
31SPAG4sperm associated antigen 4Kidney+4.130.000
32EHD2EH-domain containing 2Kidney+4.120.000
33CXCL9chemokine (C-X-C motif) ligand 9Kidney+4.110.001
34LOXlysyl oxidaseKidney+4.100.000
35CCNE2cyclin E2Kidney+4.080.000
36ENO2enolase 2 (gamma, neuronal)Kidney+4.080.000
37COL23A1collagen, type XXIII, alpha 1Kidney+4.030.003
38RGS1regulator of G-protein signaling 1Kidney+4.030.000
39CD86CD86 moleculeKidney+3.990.000
40CYP2J2cytochrome P450, family 2, subfamily J, polypeptide 2Kidney+3.990.023
41HAPLN1hyaluronan and proteoglycan link protein 1Kidney+3.980.009
42TLR8toll-like receptor 8Kidney+3.980.000
43ST8SIA4ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4Kidney+3.900.000
44AHNAK2AHNAK nucleoprotein 2Kidney+3.900.000
45RLTPRRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containingBlood-3.890.000
46BIRC3baculoviral IAP repeat containing 3Kidney+3.880.000
47TTKTTK protein kinaseKidney+3.880.000
48HIST1H2AGhistone cluster 1, H2agKidney+3.870.007
49LILRB2leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2Kidney+3.870.000
50LOC100289026putative uncharacterized protein FLJ00310-likeKidney+3.860.006
51C4orf47chromosome 4 open reading frame 47Kidney+3.850.000
52CD248CD248 molecule, endosialinBlood-3.840.000
53INHBBinhibin, beta BKidney+3.840.001
54PLA2G7phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)Kidney+3.840.003
55CPceruloplasmin (ferroxidase)Kidney+3.830.021
56BRIP1BRCA1 interacting protein C-terminal helicase 1Kidney+3.830.003
57HMHA1histocompatibility (minor) HA-1Kidney+3.830.000
58GAS2L3growth arrest-specific 2 like 3Kidney+3.830.000
59SPIBSpi-B transcription factor (Spi-1/PU.1 related)Blood-3.810.000
60TEX11testis expressed 11Kidney+3.790.029
61HILPDAhypoxia inducible lipid droplet-associatedKidney+3.790.000
62TREM2triggering receptor expressed on myeloid cells 2Kidney+3.790.000
63BHLHE41basic helix-loop-helix family, member e41Kidney+3.720.000
64TMCC1transmembrane and coiled-coil domain family 1Kidney+3.720.000
65KIF20Akinesin family member 20AKidney+3.720.000
66TPX2TPX2, microtubule-associatedKidney+3.700.000
67LRRN3leucine rich repeat neuronal 3Blood-3.610.000
68AEBP1AE binding protein 1Blood-3.530.000
69LGALSLlectin, galactoside-binding-likeBlood-3.430.000
70PLEKHB1pleckstrin homology domain containing, family B (evectins) member 1Blood-3.400.000
71CD22CD22 moleculeBlood-3.380.000
72EPHB6EPH receptor B6Blood-3.300.000
73MVDmevalonate (diphospho) decarboxylaseBlood-3.260.000
74FBLN2fibulin 2Blood-3.260.000
75FBXL16F-box and leucine-rich repeat protein 16Blood-3.230.000
76CR2complement component (3d/Epstein Barr virus) receptor 2Blood-3.210.000
77PRSS33protease, serine, 33Blood-3.210.000
78GNPNAT1glucosamine-phosphate N-acetyltransferase 1Blood-3.190.000
79RTKN2rhotekin 2Blood-3.190.000
80EPHA1EPH receptor A1Blood-3.160.000
81CRIP2cysteine-rich protein 2Blood-3.150.000
82SERINC5serine incorporator 5Blood-3.120.000
83HKDC1hexokinase domain containing 1Blood-3.110.000
84NT5E5'-nucleotidase, ecto (CD73)Blood-3.100.000
85PMEPA1prostate transmembrane protein, androgen induced 1Blood-3.090.000
86FCGBPFc fragment of IgG binding proteinBlood-3.070.000
87SALL2spalt-like transcription factor 2Blood-3.060.000
88GPA33glycoprotein A33 (transmembrane)Blood-3.020.000
89SLC27A5solute carrier family 27 (fatty acid transporter), member 5Blood-3.000.000

Search GEO for disease gene expression data for Renal Cell Carcinoma.

Compounds for genes affiliated with Renal Cell Carcinoma

About this section
44Novoseek, 24HMDB
See all sources

Compounds related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
idCompoundScoreTop Affiliating Genes
1nnmt4410.7HNF1A, HNF1B
2glucose4410.7HNF1A, HNF1B, CA9, VHL, MET, MME
3proline4410.7TFE3, MET, VHL, CA9, HNF1A
4pyrimidine44 2411.6HNF1A, OGG1, NONO
5rapamycin4410.6CA9, VHL, MET, FLCN
6oligonucleotide4410.6MET, VHL, HNF1B, HNF1A, OGG1
7adriamycin4410.5OGG1, MET, MME
8crcs4410.5MET, MME
9thymidine44 2411.5MME, MET, HNF1A, OGG1
10oxygen44 2411.3MME, MET, VHL, CA9, OGG1
11estrogen4410.1HNF1A, CA9, VHL, MET, MME

GO Terms for genes affiliated with Renal Cell Carcinoma

About this section

Cellular components related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:000563410.4KANK1, FLCN, FAM107A, ASPSCR1, PRCC, VHL
2nucleolusGO:000573010.1NONO, TFE3, PRCC, VHL, CA9, HNF1B

Biological processes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1regulation of pronephros sizeGO:003556510.7HNF1A, HNF1B
2positive regulation of transcription initiation from RNA polymerase II promoterGO:006026110.7HNF1A, HNF1B
3glucose homeostasisGO:004259310.6ASPSCR1, MET, HNF1A
4negative regulation of Rho protein signal transductionGO:003502410.6FLCN, KANK1
5positive regulation of transcription from RNA polymerase II promoterGO:004594410.6TFE3, FLCN, MET, HNF1B, HNF1A
6regulation of transcription from RNA polymerase II promoter in response to hypoxiaGO:006141810.5CA9, VHL
7branching morphogenesis of an epithelial tubeGO:004875410.5HNF1B, MET
8positive regulation of cell adhesionGO:004578510.5FLCN, TFE3
9insulin secretionGO:003007310.4HNF1B, HNF1A
10placenta developmentGO:000189010.2MET, PBRM1

Molecular functions related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription regulatory region DNA bindingGO:004421210.5HNF1A, HNF1B, TFE3
2protein bindingGO:000551510.1NONO, KANK1, FLCN, RNF139, MME, ASPSCR1

Sources for Renal Cell Carcinoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet